Avalon leads $17M round for regenerative med biotech Ankasa

La Jolla, CA-based Avalon Ventures led a $17 million A round for Ankasa Regenerative Therapeutics, handing over an $8.5 million tranche to an upstart biotech working on new technology for reactivating stem cells and tissue regeneration. The lead project at Ankasa is the stem cell growth factor WNT3A for spinal fusion surgery patients. So far, the company has been working on animal models for bone repair. Germany's Heraeus Medical and Correlation Ventures of San Diego also backed the round. "We believe that our WNT3A therapy holds the promise of significantly enhancing the success rate of many bone repair and fusion surgeries," says CEO Sanford Madigan. "As the general population ages and the number of these surgeries rises, we feel our therapeutic approach can play a positive role for patient outcomes." Release

Suggested Articles

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Grid Therapeutics is planning to start trials of its lead cancer immunotherapy GT103 next year after raising $5 million in second-round financing.

The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.